Increasing mixed chimerism is an important prognostic factor for unfavorable outcome in children with acute lymphoblastic leukemia after allogeneic stem-cell transplantation: possible role for pre-emptive immunotherapy?

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Journal of Clinical Oncology

• Publication date

  2004-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2004.05.198PMID 15117992
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Quantitative analysis of chimerism after allogeneic stem cell transplantation by PCR amplification of microsatellite markers and capillary electrophoresis with fluorescence detection: the Tuebingen experience

  2003cited by this paper
• T-cell therapy of leukemia.

  2002cited by this paper
• Donor lymphocyte infusions to treat hematologic malignancies in relapse after allogeneic blood or marrow transplantation.

  2002cited by this paper
• Second allogeneic hematopoietic stem cell transplantation in hematologic malignancies in children: long-term results of a multicenter study of the Spanish Working Party for Bone Marrow Transplantation in Children (GETMON).

  2002cited by this paper
• Sequential monitoring of chimerism and detection of minimal residual disease after allogeneic blood stem cell transplantation (BSCT) using multiplex PCR amplification of short tandem repeat-markers

  2001cited by this paper
• Analysis of chimerism within specific leukocyte subsets for detection of residual or recurrent leukemia in pediatric patients after allogeneic stem cell transplantation

  2001cited by this paper
• Progress in chimerism analysis in childhood malignancies – the dilemma of biostatistical considerations and ethical implications

  2001cited by this paper
• Second allogeneic bone marrow transplantation in acute leukemia: results of a survey by the European Cooperative Group for Blood and Marrow Transplantation.

  2001cited by this paper
• Characterization of lineage‐specific chimaerism in patients with acute leukaemia and myelodysplastic syndrome after allogeneic stem cell transplantation before and after relapse

  2000cited by this paper
• Management of Graft-Versus-Host Disease in Paediatric Bone Marrow Transplant Recipients

  2000cited by this paper
• Graft versus host disease prophylaxis with low-dose cyclosporine-A reduces the risk of relapse in children with acute leukemia given HLA-identical sibling bone marrow transplantation: results of a randomized trial.

  2000cited by this paper
• Prevention of relapse in pediatric patients with acute leukemias and MDS after allogeneic SCT by early immunotherapy initiated on the basis of increasing mixed chimerism: a single center experience of 12 children

  1999cited by this paper
• Rapid quantification of mixed chimerism using multiplex amplification of short tandem repeat markers and fluorescence detection

  1999cited by this paper
• Graft-versus-tumor induction with donor leukocyte infusions as primary therapy for patients with malignancies.

  1999cited by this paper
• Serial and quantitative analysis of mixed hematopoietic chimerism by PCR in patients with acute leukemias allows the prediction of relapse after allogeneic BMT

  1998cited by this paper
• Graft-versus-leukemia effects in T lineage and B lineage acute lymphoblastic leukemia

  1998cited by this paper
• GVHD: overview on pathophysiology, incidence, clinical and biological features.

  1998cited by this paper
• Allogeneic Cell‐Mediated and Cytokine‐Activated Immunotherapy for Malignant Lymphoma at the Stage of Minimal Residual Disease After Autologous Stem Cell Transplantation

  1998cited by this paper
• Donor Leukocyte Transfusions for Treatment of Leukemic Relapse after Bone Marrow Transplantation

  1998cited by this paper
• Monitoring of lineage-specific chimaerism allows early prediction of response following donor lymphocyte infusions for relapsed chronic myeloid leukaemia

  1998cited by this paper
• Outcome of acute leukemia relapsing after bone marrow transplantation: utility of second transplants and adoptive immunotherapy

  1997cited by this paper
• Adoptive immunotherapy for relapsed multiple myeloma after allogeneic bone marrow transplantation (BMT): evidence for a graft-versus-myeloma effect

  1997cited by this paper
• Early cyclosporine taper in high-risk sibling allogeneic bone marrow transplants

  1997cited by this paper
• Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.

  1997cited by this paper
• Additional immunotherapy on the basis of increasing mixed hematopoietic chimerism after allogeneic BMT in children with acute leukemia: is there an option to prevent relapse?

  1997cited by this paper
• Donor lymphocyte infusions (DLI) in patients with chronic myeloid leukemia following allogeneic bone marrow transplantation

  1997cited by this paper
• Induction of graft-versus-host disease as immunotherapy of leukemia relapsing after allogeneic transplantation: single-center experience of 32 adult patients

  1997cited by this paper
• Mixed hematopoietic chimerism after allogeneic bone marrow transplantation: the impact of quantitative PCR analysis for prediction of relapse and graft rejection in children

  1997cited by this paper
• Adoptive immunotherapy with donor lymphocyte transfusions.

  1997cited by this paper
• Bone marrow chimerism and transplantation tolerance.

  1997cited by this paper
• Graft-versus-myeloma effect in two cases.

  1996cited by this paper
• Patterns of hematopoietic chimerism following bone marrow transplantation for childhood acute lymphoblastic leukemia from volunteer unrelated donors.

  1996cited by this paper
• Adoptive immunotherapy with donor mononuclear cell infusions to treat relapse of acute leukemia or myelodysplasia after allogeneic bone marrow transplantation.

  1996cited by this paper
• The immunobiology of T cell therapies for leukemias.

  1996cited by this paper
• Quantitative assessment of mixed hematopoietic chimerism by polymerase chain reaction after allogeneic BMT.

  1996cited by this paper
• Graft-versus-leukemia effect and its clinical implications.

  1996cited by this paper
• Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation.

  1996cited by this paper
• Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients.

  1995cited by this paper
• Cytokine-mediated immunotherapy with or without donor leukocytes for poor-risk acute myeloid leukemia relapsing after allogeneic bone marrow transplantation.

  1995cited by this paper
• Adoptive immunotherapy using donor leukocytes following bone marrow transplantation for chronic myeloid leukemia: is T cell dose important in determining biological response?

  1995cited by this paper
• Immunotherapy with donor leukocyte infusions for patients with relapsed acute myeloid leukemia following partially mismatched related donor bone marrow transplantation.

  1995cited by this paper
• Delayed infusion of immunocompetent donor cells after bone marrow transplantation breaks graft-host tolerance allows for persistent antileukemic reactivity without severe graft-versus-host disease.

  1995cited by this paper
• Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease.

  1995cited by this paper
• Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: the case for giving donor leukocyte transfusions before the onset of hematologic relapse.

  1994cited by this paper
• Treatment of acute lymphoblastic leukemia. 30 years' experience at St. Jude Children's Research Hospital.

  1993cited by this paper
• The graft-vs.-leukemia effect. Implications for post-marrow transplant antileukemia treatment.

  1993cited by this paper
• Hematologic relapse of chronic myelogenous leukemia following allogeneic bone marrow transplantation: apparent graft-versus-leukemia effect following abrupt discontinuation of immunosuppression.

  1992cited by this paper
• Treatment of childhood acute lymphoblastic leukaemia: present issues and future prospects.

  1992cited by this paper
• Second transplants for leukaemic relapse after bone marrow transplantation: high early mortality but favourable effect of chronic GVHD on continued remission. A REPORT BY THE EBMT LEUKAEMIA WORKING PARTY

  1991cited by this paper
• T-cell depletion of HLA-identical transplants in leukemia.

  1991cited by this paper
• Donor Leukocyte Transfusions for Treatment of Recurrent Chronic Myelogenous Leukemia in Marrow Transplant Patients

  1990cited by this paper
• Bone marrow transplantation as a means of inducing tolerance.

  1990cited by this paper
• Graft-versus-leukemia reactions after bone marrow transplantation.

  1990cited by this paper
• Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients.

  1990cited by this paper
• Mixed hematopoietic chimerism after allogeneic transplantation with lymphocyte-depleted bone marrow is not associated with a higher incidence of relapse.

  1989cited by this paper
• Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts.

  1979cited by this paper
• CLINICAL MANIFESTATIONS OF GRAFT‐VERSUS-HOST DISEASE IN HUMAN RECIPIENTS OF MARROW FROM HL‐A-MATCHED SIBLING DONOR,S

  1974cited by this paper
• Nonparametric Estimation from Incomplete Observations

  1958cited by this paper

• POST-TRANSPLANT RELAPSE IN ACUTE LEUKEMIA: COMPARATIVE VALUE OF MRD AND CHIMERISM.

  2026cites this paper
• Chimerism and a framework for clinical practice: A report from the Cellular Therapies Section Coordinating Committee (CTSCC) of Association for Advancement of Blood and Biotherapies (AABB).

  2026cites this paper
• Analysis of risk factors for relapse after allogeneic hematopoietic stem cell transplantation in acute leukemia

  2025cites this paper
• Prophylactic donor lymphocyte infusions after first allogeneic hematopoietic stem cell transplantation in children with acute leukemia

  2025influential citation
• NGS‐MRD negativity in post‐HSCT ALL spares unnecessary therapeutic interventions triggered by borderline qPCR results without an increase in relapse risk

  2025cites this paper
• Challenges and Opportunities in the Care of Hematopoietic Cell Transplant Survivors in the Modern Era.

  2025cites this paper
• A clinical solution for tracking clonal evolution of acute myeloid leukemia after allogeneic transplantation using bulk next generation sequencing

  2025cites this paper
• Long-Term Donor Chimerism Monitoring for Relapse Risk Assessment After Pediatric Allo-HSCT

  2025cites this paper
• Early mixed donor chimerism is a strong negative prognostic indicator in allogeneic stem cell transplant for AML and MDS.

  2024cites this paper
• The unnecessary use of short tandem repeat testing on bone marrow samples in patients after 1 year following allogeneic hematopoietic stem cell transplant.

  2024cites this paper
• Sensitivity and Specificity of Chimerism Tests in Predicting Leukemia Relapse Using Increasing Mixed Chimerism.

  2024cites this paper
• Post-transplant relapse in pediatric acute lymphoblastic leukemia in the era of CAR-T cell therapy. A multicenter analysis of Grupo Español de Trasplante Hematopoyetico y Terapia Celular (GETH-TC) Pediatric Committee.

  2024cites this paper
• Performance Characteristics of NGS-Based Engraftment Monitoring and Microchimerism Detection in Allogeneic Hematopoietic Cell Transplantation: A Practical Approach for Clinical Assay Validation.

  2024cites this paper
• Donor lymphocyte infusion for prophylaxis and treatment of relapse in pediatric hematologic malignancies after allogeneic hematopoietic stem cell transplant

  2023cites this paper
• Highly-sensitive chimerism analysis in blood after allogeneic hematopoietic cell transplantation in childhood leukemia: Results from the Nordic Microchimerism Study

  2023cites this paper
• Immunophenotypic measurable residual disease monitoring in adult acute lymphoblastic leukemia patients undergoing allogeneic hematopoietic stem cell transplantation

  2023cites this paper
• The current landscape: Allogeneic hematopoietic stem cell transplant for acute lymphoblastic leukemia.

  2023cites this paper
• Peripheral blood CD34 donor chimerism has greater clinical utility than CD3 for detecting relapse after allogeneic stem cell transplantation for AML or MDS.

  2023cites this paper
• Post-Hematopoietic Cell Transplantation Relapsed Acute Lymphoblastic Leukemia: Current Challenges and Future Directions

  2023cites this paper
• Ultrasensitive chimerism enhances measurable residual disease testing after allogeneic hematopoietic cell transplantation

  2023cites this paper
• Current Prophylaxis and Treatment Approaches for Acute Graft-Versus-Host Disease in Haematopoietic Stem Cell Transplantation for Children With Acute Lymphoblastic Leukaemia

  2022cites this paper
• Post-transplant day +100 MRD detection rather than mixed chimerism predicts relapses after allo-SCT for intermediate risk AML patients transplanted in CR.

  2022cites this paper
• Is It Possible to Separate the Graft-Versus-Leukemia (GVL) Effect Against B Cell Acute Lymphoblastic Leukemia From Graft-Versus-Host Disease (GVHD) After Hematopoietic Cell Transplant?

  2022cites this paper
• Chimerism Analysis of Children with Allogeneic Stem-Cell transplantation and Its Effect on Survival

  2022influential citation
• Could (should) we abandon total body irradiation for conditioning in children with leukemia.

  2022cites this paper
• Chimerism analysis for clinicians: a review of the literature and worldwide practices

  2022cites this paper
• The mythological chimera and new era of relapse prediction post-transplant.

  2022cites this paper
• Bispecific Antibodies and Other Non-CAR Targeted Therapies and HSCT: Decreased Toxicity for Better Transplant Outcome in Paediatric ALL?

  2022cites this paper
• CD19+ lineage chimerism, an early biomarker after anti-CD19 CAR-T cell therapy in patients previously receiving a hematopoietic stem cell transplantation

  2022cites this paper
• The Role of Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Leukemia

  2021cites this paper
• Defining the Role of Donor Lymphocyte Infusion in High-Risk Hematologic Malignancies.

  2021cites this paper
• Minimal Residual Disease Prior to and After Haematopoietic Stem Cell Transplantation in Children and Adolescents With Acute Lymphoblastic Leukaemia: What Level of Negativity Is Relevant?

  2021cites this paper
• Blinatumomab Maintenance After Allogeneic Hematopoietic Cell Transplantation for B-lineage Acute Lymphoblastic Leukemia.

  2021cites this paper
• HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA

  2021cites this paper
• Bone Marrow Engraftment Analysis

  2021cites this paper
• Multivariate Analysis of Immune Reconstitution and Relapse Risk Scoring in Children Receiving Allogeneic Stem Cell Transplantation for Acute Leukemias

  2021cites this paper
• A practical guide to chimerism analysis: Review of the literature and testing practices worldwide.

  2021cites this paper
• Prognostic factors for survival in children who relapsed after allogeneic hematopoietic stem cell transplantation for acute leukemia

  2020cites this paper
• Monitoring minimal residual/relapsing disease after allogeneic haematopoietic stem cell transplantation in adult patients with acute lymphoblastic leukaemia

  2020cites this paper
• Detection and monitoring of lineage-specific chimerism by digital droplet PCR-based testing of deletion/insertion polymorphisms.

  2020cites this paper
• The effect of the minimum residual disease on the risk of relapse at allogeneic hematopoietic stem cell transplantation in children, adolescents, and young adults with acute lymphoblastic leukemia

  2020cites this paper
• Is microchimerism a sign of imminent disease recurrence after allogeneic hematopoietic stem cell transplantation? A systematic review of the literature.

  2020cites this paper
• Digital droplet PCR‐based chimerism analysis for monitoring of hematopoietic engraftment after allogeneic stem cell transplantation

  2019cites this paper
• Highly sensitive chimerism detection in blood is associated with increased risk of relapse after allogeneic hematopoietic cell transplantation in childhood leukemia

  2019cites this paper
• Allogeneic stem cell transplantation in the era of novel therapies for acute lymphoblastic leukaemia.

  2019cites this paper
• More precisely defining risk peri-HCT in pediatric ALL: pre- vs post-MRD measures, serial positivity, and risk modeling.

  2019cites this paper
• Allogeneic stem cell transplantation in the era of novel therapies for acute lymphoblastic leukaemia

  2019cites this paper
• Personalized Chimerism Test that Uses Selection of Short Tandem Repeat or Quantitative PCR Depending on Patient's Chimerism Status.

  2019cites this paper
• Clearance of Hematologic Malignancies by Allogeneic Cytokine-Induced Killer Cell or Donor Lymphocyte Infusions.

  2019cites this paper
• Accurate and Efficient Chimerism Determination Using the SNP-Based Chimeric ID Panel from Agena Bioscience

  2019cites this paper
• Impact of early chimerism status on clinical outcome in children with acute lymphoblastic leukaemia after haematopoietic stem cell transplantation

  2019cites this paper
• Monitoring of Chimerism in Rare Haematological Malignant Diseases after Allogeneic Haematopoietic Stem Cell Transplantation

  2019cites this paper
• Dinámica del quimerismo en sangre periférica, médula ósea y linajes leucocitarios en el trasplante alogénico de progenitores hematopoyéticos

  2019influential citation
• Biology-Driven Approaches to Prevent and Treat Relapse of Myeloid Neoplasia after Allogeneic Hematopoietic Stem Cell Transplantation.

  2019cites this paper
• Advances in hematopoietic cell transplant for the treatment of hematologic malignancies

  2019cites this paper
• IL12 and IFNγ secretion by donor mononuclear cells in response to host antigens may predict acute GVHD after HSCT.

  2019cites this paper
• Early achievement of full donor chimerism after allogeneic hematopoietic stem cell transplantation predicts lower relapse risk in patients with acute lymphoblastic leukemia

  2018cites this paper
• Hematopoietic Stem Cell Transplantation for Adult Philadelphia-Negative Acute Lymphoblastic Leukemia in the First Complete Remission in the Era of Minimal Residual Disease

  2018cites this paper
• Diagnostic value of highly-sensitive chimerism analysis after allogeneic stem cell transplantation

  2018cites this paper
• Documentation of Engraftment and Chimerism After HSCT

  2018cites this paper
• The European Blood and Marrow Transplantation Textbook for Nurses

  2018cites this paper
• AlloHSCT in paediatric ALL and AML in complete remission: improvement over time impacted by accreditation?

  2018cites this paper
• Influence of pre-transplant minimal residual disease on prognosis after Allo-SCT for patients with acute lymphoblastic leukemia: systematic review and meta-analysis

  2018cites this paper
• Reversal of Low Donor Chimerism after Hematopoietic Cell Transplantation Using Pentostatin and Donor Lymphocyte Infusion: A Prospective Phase II Multicenter Trial.

  2018cites this paper
• Outcome of relapse after allogeneic HSCT in children with ALL enrolled in the ALL‐SCT 2003/2007 trial

  2018cites this paper
• Engraftment and Chimerism

  2018cites this paper
• Engraftment, Graft Failure, and Rejection

  2018influential citation
• Safety of pre-emptive donor lymphocyte infusions (DLI) based on mixed chimerism (MC) in peripheral blood or bone marrow subsets in children undergoing hematopoietic stem cell transplant (HSCT) for hematologic malignancies

  2017cites this paper
• Monitoring of Chimerism Following Hematopoietic Stem Cell Transplantation

  2017cites this paper
• Factors Associated with Long-Term Risk of Relapse after Unrelated Cord Blood Transplantation in Children with Acute Lymphoblastic Leukemia in Remission.

  2017cites this paper
• When Less Is Good, Is None Better? The Prognostic and Therapeutic Significance of Peri-Transplant Minimal Residual Disease Assessment in Pediatric Acute Lymphoblastic Leukemia

  2017cites this paper
• Impact of post‐transplant minimal residual disease on the clinical outcome of pediatric acute leukemia

  2017cites this paper
• Pre-Emptive Immunotherapy for Clearance of Molecular Disease in Childhood Acute Lymphoblastic Leukemia after Transplantation.

  2017cites this paper
• Early mixed chimerism‐based preemptive immunotherapy in children undergoing allogeneic hematopoietic stem cell transplantation for acute leukemia

  2017cites this paper
• Usefulness of Post-Transplant Hematopoietic Chimera Monitoring by Use of the Quantitative Fluorescence Polymerase Chain Reaction Method.

  2017cites this paper
• Comparison of outcomes after donor lymphocyte infusion with or without prior chemotherapy for minimal residual disease in acute leukemia/myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation

  2017cites this paper
• Engraftment and graft failure: Assessment and practical considerations

  2017cites this paper
• Utilidad clínica del seguimiento cuantitativo del quimerismo en leucocitos activados y linfocitos T reguladores post trasplante alogénico de progenitores hematopoyéticos

  2016cites this paper
• Risk assessment of relapse by lineage-specific monitoring of chimerism in children undergoing allogeneic stem cell transplantation for acute lymphoblastic leukemia

  2016cites this paper
• Peripheral blood late mixed chimerism in leucocyte subpopulations following allogeneic stem cell transplantation for childhood malignancies: does it matter?

  2016cites this paper
• A technical application of quantitative next generation sequencing for chimerism evaluation

  2016cites this paper
• Detection of Low Level Mixed Chimerism Using High Throughput SNP Genotyping

  2016cites this paper
• Preparation of Cytokine-activated NK Cells for Use in Adoptive Cell Therapy in Cancer Patients: Protocol Optimization and Therapeutic Potential

  2016cites this paper
• Chimerism interpretation with a highly sensitive quantitative PCR method: 6 months median latency before chimerism drop below 0.1%

  2016cites this paper
• Chimerism Testing in Allogeneic Hematopoietic Stem Cell Transplantation

  2016cites this paper
• Interleukin-15-activated cytokine-induced killer cells may sustain remission in leukemia patients after allogeneic stem cell transplantation: feasibility, safety and first insights on efficacy

  2016cites this paper
• Donor Chimerism of B Cells and Nature Killer Cells Provides Useful Information to Predict Hematologic Relapse following Allogeneic Hematopoietic Stem Cell Transplantation

  2015cites this paper
• Enfermedad minima residual medida mediante citometria de flujo multiparametrica en niños con leucemia linfoblastica aguda sometidos a trasplante alogenico de progenitores hematopoyeticos

  2015influential citation
• Chimerism-based pre-emptive immunotherapy with fast withdrawal of immunosuppression and donor lymphocyte infusions after allogeneic stem cell transplantation for pediatric hematologic malignancies.

  2015influential citation
• Detection of relapse after hematopoietic stem cell transplantation in childhood by monitoring of WT1 expression and chimerism

  2015cites this paper
• Risk factors and timing of relapse after allogeneic transplantation in pediatric ALL: for whom and when should interventions be tested?

  2015cites this paper
• Follow‐up of post‐transplant minimal residual disease and chimerism in childhood lymphoblastic leukaemia: 90 d to react

  2015influential citation
• Adoptive therapy with donor lymphocyte infusion after allogenic hematopoietic SCT in pediatric patients

  2015cites this paper
• Chimerism analysis in peripheral blood using indel quantitative real-time PCR is a useful tool to predict post-transplant relapse in acute leukemia

  2015cites this paper
• Monitoring of Hematopoietic Chimerism by Real-Time Quantitative PCR of Micro Insertions/Deletions in Samples with Low DNA Quantities

  2015cites this paper
• Achievement of early complete donor chimerism in CD25+-activated leukocytes is a strong predictor of the development of graft-versus-host-disease after stem cell transplantation.

  2015cites this paper
• Cytomegalovirus-specific cytokine-induced killer cells: concurrent targeting of leukemia and cytomegalovirus.

  2015cites this paper
• Monitoring of minimal residual disease after allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia allows for the identification of impending relapse: results of the ALL-BFM-SCT 2003 trial.

  2015cites this paper
• Feasibility of treating post-transplantation minimal residual disease in children with acute leukemia.

  2014cites this paper
• New frontiers in pediatric Allo-SCT: novel approaches for children and adolescents with ALL

  2014cites this paper